Clinical trial · Interventional
Memory Perception Assessment in Central/Non-central Nervous System Cancers
Prospective and Retrospective Memory Perception Assessment in Central/Non-central Nervous System Cancers
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prospective memory (PM) is the ability to implement intended actions in the future. It allows maintaining and retrieving future plans, goals, and activities (i.e., remember to remember). PM is associated with most everyday memory problems . PM is crucial to correctly respond to all the social, occupational and working demands of everyday life, to perform many deferred health-related actions and is involved in therapeutic adherence . Indeed, PM errors are an important part of the aging memory complaints. The prevalence of self-reported PM failures is also significant among young adults, compared with self-reported retrospective memory (RM) failures .Yet, PM errors are major sources of frustration and embarrassment . In oncology, recently investigated the self-reported memory complaints in a 80 case-healthy-control study breast patients . Subjective memory complaints were assessed using the Prospective and Retrospective Memory Questionnaire . Results from the Paquet et al. study show that all participants (i.e., both patients and matched-controls) reported more PM than RM failures in daily-life (p\<.001). Breast cancer patients reported more RM and PM failures than controls. However, this group effect was no longer statistically significant when controlling for depression and fatigue. These findings are consistent with the view that memory complaints are closely associated with depression and cancer-related fatigue, and more generally with psychopathological variables .As underlined by Paquet et al. subjective memory complaints should be investigated because they refer to some aspects of the cancer experience that could potentially be linked to quality of life. Thus, it is important to explore psychopathological basis such as depression, anxiety and fatigue while investigating self-reported memory failures in cancer patients. Despites the importance of PM, there have been, to our knowledge, only few studies evaluating PM complaints or PM functioning in patients diagnosed with an intracerebral tumor (such as Diffuse Low-Grade Glioma- DLGG- or glioblastome- GB) or extra-cerebral tumor (such as breast cancer - BC). Therefore, the investigators thought it would be useful, as a first step, to conduct a study to explore and to manage the PM and RM subjective complaints in cancer patients compared to another chronic disease, such as HIV. In fine, these data will help to identify a new target for psychological management focused on either psychopathological or neuropsychological rehabilitation
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
| Glioma | Glioma | ONTOLOGY_EXACT | 0.98 |
| Healthy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| QMRP questionnaire | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- OTHER
- label
- GLIOBLASTOMA
- description
- One visit with collection : demographical data clinical data QMRP questionnaire HADS questionnaire MFI questionnaire MoCA test FAB test
- interventionNames
- Other: QMRP questionnaire
- type
- OTHER
- label
- glioma
- description
- One visit with collection : demographical data clinical data QMRP questionnaire HADS questionnaire MFI questionnaire MoCA test FAB test
- interventionNames
- Other: QMRP questionnaire
- type
- OTHER
- label
- breast cancer
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: All the participants must fulfill all the following criteria to be eligible for study entry: * Be aged of 18 to 80 years old * Have a ECOG Performance Status ≤ 2 or a Karnofsky index ≥ 50 % * Have a satisfactory level of French * Have signed the informed consent Also, for the DLGG group, the patients must: * Have a histologically-proven diagnosis of DLGG (i.e., WHO grade II glioma) * Receive or have received a first oncological treatment after surgery (chemotherapy, radiation therapy…) Also, for the GB group, the patients must: \- Have a histologically-proven diagnosis of GB (i.e., WHO grade IV glioma). Also, for the breast cancer group, the patients must: \- Have a histologically-proven diagnosis of breast cancer diagnosed \< 2 years. Exclusion Criteria: Participants presenting with any of the following exclusion criteria will not be included in the study: * Patients with brain metastases * Patients under tutorship or curatorship or protective measures * Patients suffering from sensorial or motor deficits avoiding the tests administration * Patients with a reported history of psychiatric disease (e.g., mental retardation, psychotic disorders, learning disabilities, attention-deficit/hyperactivity disorder, and bipolar disorder) * Have reported a substance dependence within the past six months (e.g., cocaine or methamphetamine dependence) * Pregnant women * Legal incapacity or physical, psychological social or geographical status interfering with the patient's ability to sign the informed consent or to terminate the study Also, for the DLGG group, the patients must not: * Have an anaplastic glioma (i.e., WHO grade III glioma) * Have a DLGG with radiological or histological signs of anaplastic transformation * Have a history of HIV * Have a history of other cancer Also, for the GB group, the patients must not: * Patients treated with ≥2 lines of systemic cancer treatment (e.g., patient after the first GB recurrence) * Have a history of HIV * Have a history of other cancer Also, for the breast cancer group, the patients must not: * Have a metastatic disease * Have a neoadjuvant therapy * Have a documented neurological, or substance use disorders. * Have a history of HIV * Have a history of other cancer * Have reported a history of neurological diagnoses (e.g., seizure disorders, closed head injuries with loss of consciousness greater than 15 min). Also for the control group, the participants must not: * Have a documented neurological, or substance use disorders * Have a history of cancer * Have a history of HIV
References
Publications (34)
- BACKGROUNDBedard M, Verma S, Collins B, Song X, Paquet L. Prospective memory impairment in chemotherapy-exposed early breast cancer survivors: Preliminary evidence from a clinical test. J Psychosoc Oncol. 2016 Jul-Aug;34(4):291-304. doi: 10.1080/07347332.2016.1181133. Epub 2016 Apr 28. PMID 27123566
- BACKGROUNDBoone M, Roussel M, Chauffert B, Le Gars D, Godefroy O. Prevalence and profile of cognitive impairment in adult glioma: a sensitivity analysis. J Neurooncol. 2016 Aug;129(1):123-30. doi: 10.1007/s11060-016-2152-7. Epub 2016 May 30. PMID 27241133
- BACKGROUNDBrem S, Meyers CA, Palmer G, Booth-Jones M, Jain S, Ewend MG. Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers. Cancer. 2013 Nov 1;119(21):3830-8. doi: 10.1002/cncr.28307. Epub 2013 Aug 23. PMID 24037801
- BACKGROUNDCheng H, Yang Z, Dong B, Chen C, Zhang M, Huang Z, Chen Z, Wang K. Chemotherapy-induced prospective memory impairment in patients with breast cancer. Psychooncology. 2013 Oct;22(10):2391-5. doi: 10.1002/pon.3291. Epub 2013 May 15. PMID 23674402
- BACKGROUNDCrawford JR, Henry JD, Ward AL, Blake J. The Prospective and Retrospective Memory Questionnaire (PRMQ): latent structure, normative data and discrepancy analysis for proxy-ratings. Br J Clin Psychol. 2006 Mar;45(Pt 1):83-104. doi: 10.1348/014466505X28748. PMID 16480568
- BACKGROUNDde Frias CM, Dixon RA, Backman L. Use of memory compensation strategies is related to psychosocial and health indicators. J Gerontol B Psychol Sci Soc Sci. 2003 Jan;58(1):P12-22. doi: 10.1093/geronb/58.1.p12. PMID 12496297
- BACKGROUNDDieckmann P, Reddersen S, Wehner T, Rall M. Prospective memory failures as an unexplored threat to patient safety: results from a pilot study using patient simulators to investigate the missed execution of intentions. Ergonomics. 2006 Apr 15-May 15;49(5-6):526-43. doi: 10.1080/00140130600568782.